NEW YORK (GenomeWeb News) – Goldman Sachs today resumed coverage of Danaher with a Neutral rating and a 12-month price target of $57.

In a research note analyst Isaac Ro said that the Washington-based conglomerate will need to rejuvenate its M&A pipeline to spark growth in the midst of few near-term catalysts for organic growth.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.

Wired reports that 23andMe is trying to bolster its outside collaborations.